All In Biotech

Drug Trial Radar · NCT03798054

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

A Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)

Last checked: Nov 20, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 878 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

878

Actual

Start

Feb 15, 2019

Primary completion

Mar 1, 2021

Study completion Mar 1, 2021

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: The co-primary objective of this study is: * To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) versus lixisenatide on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change. * To demonstrate the non-inferiority of iGlarLixi versus insulin glargine on glycemic control as assessed by HbA1c change. Secondary Objectives: * To assess the effects of iGlarLixi in comparison with insulin glargine alone and lixisenatide alone. * To assess the safety in each treatment group.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Insulin glargine/Lixisenatide (HOE901/AVE0010)Drug

    Pharmaceutical form: solution Route of administration: subcutaneous

  • Insulin glargine (HOE901)Drug

    Pharmaceutical form: solution Route of administration: subcutaneous

  • Lixisenatide (AVE0010)Drug

    Pharmaceutical form: solution Route of administration: subcutaneous

  • MetforminDrug

    Pharmaceutical form: tablet Route of administration: oral

  • SGLT2 inhibitorDrug

    Pharmaceutical form:tablet Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: From Baseline to Week 24

Locations

79 sites in 4 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 1560001

    Beijing, China

  • Investigational Site Number 1560006

    Beijing, China

  • Investigational Site Number 1560049

    Beijing, China

  • Investigational Site Number 1560039

    Cangzhou, China

  • Investigational Site Number 1560009

    Changchun, China

  • Investigational Site Number 1560027

    Changchun, China

  • Investigational Site Number 1560016

    Changsha, China

  • Investigational Site Number 1560053

    Chengdu, China

  • Investigational Site Number 1560056

    Chengdu, China

  • Investigational Site Number 1560010

    Chenzhou, China

  • Investigational Site Number 1560037

    Chongqing, China

  • Investigational Site Number 1560050

    Chongqing, China

  • Investigational Site Number 1560044

    Dongguan, China

  • Investigational Site Number 1560033

    Guangzhou, China

  • Investigational Site Number 1560028

    Guangzhou, China

  • Investigational Site Number 1560012

    Handan, China

  • Investigational Site Number 1560023

    Hangzhou, China

  • Investigational Site Number 1560035

    Harbin, China

  • Investigational Site Number 1560036

    Harbin, China

  • Investigational Site Number 1560011

    Hengshui, China

  • Investigational Site Number 1560024

    Hohhot, China

  • Investigational Site Number 1560047

    Hohhot, China

  • Investigational Site Number 3440001

    Hong Kong, China

  • Investigational Site Number 1560026

    Huanggang, China

  • Investigational Site Number 1560025

    Huangshi, China

  • Investigational Site Number 1560048

    Huizhou, China

  • Investigational Site Number 1560034

    Huzhou, China

  • Investigational Site Number 1560005

    Jinan, China

  • Investigational Site Number 1560052

    Jinhua, China

  • Investigational Site Number 1560031

    Jinzhou, China

  • Investigational Site Number 1560022

    Nanjing, China

  • Investigational Site Number 1560014

    Nanjing, China

  • Investigational Site Number 1560043

    Nanjing, China

  • Investigational Site Number 1560041

    Nanning, China

  • Investigational Site Number 1560032

    Qingdao, China

  • Investigational Site Number 1560038

    Qinhuangdao, China

  • Investigational Site Number 1560013

    Shanghai, China

  • Investigational Site Number 1560007

    Shanghai, China

  • Investigational Site Number 1560004

    Shanghai, China

  • Investigational Site Number 1560029

    Shanghai, China

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.